Obinutuzumab in combination with bendamustine for treating rituximab rituximab, often followed by maintenance therapy with rituximab. However
Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance
This effect is more pronounced when bendamustine is combined with rituximab. Report suspected side effects to medicines, vaccines or
Fixed-duration venetoclax-rituximab outperforms bendamustine-rituximab in patients with R/R CLL treatment with venetoclax-rituximab (VenR) vs.
Bendamustine with rituximab for first line treatment of mantle cell lymphoma in adults Bendamustine for relapsed/refractory classical Hodgkin lymphoma (all
by AS Freedman Cited by 1Outline Bendamustine plus rituximab R-CHOP Obinutuzumab-based regimens Lenalidomide plus rituximab or obinutuzumab.
FCR: fludarabine, cyclophosphamide, and rituximab; BR: bendamustine and rituximab. For information about the drugs listed on this page, visit Drug Listings.
by LH Sehn 2024 Cited by 374Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a
Bendamustine plus rituximab (BR) and dexamethasone, rituximab, and cyclophosphamide (DRC) combination therapies are frequently used for the treatment of
Comments
one of my own pet peeves, sorry